UEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease
In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44 In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44 Duvakitug was well tolerated and safety was consistent with the induction study PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) […]
Teva Pharmaceuticals and Sanofi have presented new positive data from the RELIEVE UCCD phase 2b long-term extension study in patients with moderate-to-severe ulcerative colitis or Crohn's disease. The study, identified as NCT05668013, showcased that duvakitug, an investigational human monoclonal antibody targeting TL1A protein, maintained clinically significant efficacy improvements across multiple endpoints over 44 weeks.
Duvakitug works by potentially reducing inflammation and fibrosis in ulcerative colitis and Crohn's disease.
Brief written by urgent.news from Financial Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
